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Abstract 32 
There are knowledge gaps regarding evidence-based research on the burden of vaccine-33 
preventable diseases among human immunodeficiency virus (HIV)-infected and HIV-exposed 34 
children aged <18years in sub-Saharan Africa. It is therefore essential to determine the trend and 35 
burden of vaccine-preventable diseases. We completed a systematic review and meta-analysis to 36 
identify the incidence, prevalence and case-fatality rates (CFR) attributed to various vaccine-37 
preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa. The 38 
trends in the prevalence of vaccine-preventable diseases among HIV-infected and HIV-exposed 39 
children were also determined. Nine studies on tuberculosis (TB) were pooled to give an overall 40 
incidence rate estimate of 60 (95% confidence interval [CI] 30 – 70) per 1,000 child-years. The 41 
incidence of pneumococcal infections varied between 109-1509 per 100,000 while pertussis was 42 
between 2.9 and 3.7 per 1000 child-year. Twenty-two TB prevalence studies reported an estimated 43 
prevalence of 16%. Fifteen prevalence studies on hepatitis B infection were pooled together with 44 
an estimated prevalence of 5%. The pooled prevalence for pneumococcal infections was 2% while 45 
rotavirus diarrhoea reported a prevalence of 13%. Twenty-nine studies on TB were pooled to give 46 
an overall CFR estimate of 17% while pneumococcal infections in HIV-infected and exposed 47 
children were pooled together with a resultant rate of 15%. Some of the vaccine-preventable 48 
diseases still have high incidences, prevalence and CFR among HIV-infected and HIV-exposed 49 
children. There is also a dearth of research data on the burden of several vaccine-preventable 50 
diseases among HIV-infected and exposed children and a need for more studies in this area.  51 
Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; burden 52 
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Background 60 
Human immunodeficiency virus (HIV) infection remains a leading public-health challenge and a 61 
principal cause of the infectious disease burden in low- and middle-income countries especially in 62 
sub-Saharan Africa.1 This region accounts for the bulk of HIV infection with about 36.7 million 63 
people living with the disease an estimated 75% of the global burden.2,3 It was also estimated that 64 
approximately 2.1 million children aged under 15 years were living with HIV with the majority 65 
coming from sub-Saharan Africa and about 31% having access to antiretroviral therapy in 2014.4 66 
The incidence of HIV infections among children declined in 2014 but there were still 220,000 new 67 
infections that year alone.4 HIV-infected children have an increased risk of developing various 68 
vaccine-preventable diseases due to their defective immune systems.5 This makes it crucial to 69 
focus on the vaccination of HIV-infected and exposed children. The majority of these children are 70 
also residents of low-and-middle-income countries characterised by limited access to HIV 71 
diagnosis, treatment and care.2  72 
Vaccination against various vaccine-preventable diseases has been proven to be a beneficial and 73 
cost-effective public-health measure for protecting children, adolescents and adults from these 74 
diseases, thereby reducing the morbidity and mortality attributable to them.6,7 Coverage of routine 75 
vaccinations is still low in some developing countries and not sufficient to meet the Global Vaccine 76 
Action Plan (GVAP) targets.8–10 Some African countries have low or decreasing immunisation 77 
coverage over the years with some not achieving ≥ 90% national coverage for vaccines included 78 
in their national immunisation schedule by the World Health Organization (WHO) in 2016.11 Sub-79 
Saharan African countries account for about 34% of the global vaccine-preventable diseases 80 
burden, and are also responsible for the highest proportion of under-five mortality from these 81 
diseases.12   82 
Recently, most developing countries have included routine childhood vaccines such as hepatitis 83 
B; Bacillus Calmette–Guérin (BCG); diphtheria, tetanus and pertussis (DTP); Haemophilus 84 
influenzae type b (Hib); polio; pneumococcal conjugate; measles; rotavirus (RV), rubella and 85 
yellow fever vaccines in their national Expanded Programme on Immunisation (EPI).13 These 86 
vaccines also protect against diseases such as tuberculosis, poliomyelitis, rotavirus gastroenteritis, 87 
diphtheria, tetanus, pertussis, pneumococcal diseases, hepatitis B infection, rubella, measles and 88 
yellow fever.  89 
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The gap in knowledge, especially in terms of evidence-based research, on the burden of vaccine-90 
preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa, 91 
warrants this study.14 This study completed a systematic review of literature and meta-analysis to 92 
identify the incidence, prevalence and mortality due to various vaccine-preventable diseases 93 
among HIV-infected and HIV-exposed children in sub-Saharan Africa since the advent of HIV in 94 
the 1980s. This study is essential in determining the trend and current burden of vaccine-95 
preventable disease epidemiology in sub-Saharan Africa.  96 
 97 
Objectives 98 
Primary objectives 99 
1. To appraise all available published literature on the incidence and prevalence of vaccine-100 
preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, 101 
rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles, 102 
rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan 103 
Africa.  104 
2. To determine the trend in the incidence and/or prevalence of vaccine-preventable diseases 105 
such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, 106 
diphtheria, tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever 107 
among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 2018. 108 
Secondary objective 109 
1. To describe the case-fatality rate ascribed to vaccine-preventable diseases such as 110 
tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, 111 
tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever among HIV-112 
infected and HIV-exposed children in sub-Saharan Africa. 113 
 114 
Results 115 
 116 
Literature search and result 117 
Figure 1 shows the study selection process reported in line with PRISMA guidelines. We identified 118 
3430 publications through the search of different databases. We also identified 13 additional 119 
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articles through the screening of reference lists of various related articles. We screened 188 full-120 
text articles and selected 76 articles for inclusion in the review and 70 articles were suitable for 121 
the meta-analysis (Figure 1). 122 
Study characteristics 123 
Table 1 provides a summary of the included studies and the vaccine-preventable diseases of 124 
interest.  The table shows that 45 articles reported on tuberculosis, 14 on hepatitis B virus infection, 125 
ten studies focused on pneumococcal infections, two on rotavirus gastroenteritis, three on measles 126 
and three on pertussis. The included articles consist of 41 cross-sectional studies, 31 cohort studies, 127 
four case-control studies and one time-series analysis.  128 
South Africa had the highest number of published articles with 35 articles, Nigeria produced 10 129 
articles, four were from Kenya, four from Ethiopia and two studies were conducted in multiple 130 
countries. The other studies were conducted in Rwanda, Tanzania, Cote d' Ivoire, Uganda, Malawi, 131 
Botswana, Zimbabwe, Zambia, Mozambique and Swaziland (Table 1). A total of 46,882 children 132 
were included in this review.  HIV-infected children were included in 71 studies while two studies 133 
had both HIV-infected and HIV-exposed uninfected children, and one study with only HIV-134 
exposed children. The included studies were conducted between 1992 and 2016. 135 
Using the Newcastle-Ottawa Quality Scale for the quality assessment of the eligible studies, 11 136 
articles scored eight points; 15 articles scored seven points; 27 articles scored six points; 15 articles 137 
scored five points; seven articles scored four points and two articles scored three points. The 138 
characteristics of the eligible studies are summarised in Table 1. 139 
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 147 
Figure 1: Flow diagram of the selection process 148 
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 Table 1: Characteristics of the study population 
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 1 
Incidence rates  2 
Tuberculosis: Nine studies15,17-20,22,32,35 on TB were pooled to give an overall incidence rate 3 
estimate of 60 (95% CI 30 – 70) per 1,000 child-years at risk for tuberculosis based on a 4 
random-effects model (I2 = 99%; Figure 2). Subgroup analysis established change over time in 5 
incidence rates when comparing studies conducted before and after 2011. The pooled incidence 6 
rates for tuberculosis in those conducted before 2010 was 70 (95% CI -20 - 160) per 1,000 7 
child-years32,35 and 40 (95% CI 20 - 50) per 1,000 child-years in studies conducted between 8 
2011 and 2018.15,17-20,22 The heterogeneity of the TB incidence could not be explained by the 9 
subgroup analysis. Kouakoussui et al. reported TB incidence of 0.71 per 100 child/months 10 
before initiation of highly active antiretroviral therapy (HAART) and 0.16 per 100 11 
child/months during HAART treatment among Ivorian HIV-infected children.60 12 
Pneumococcal infections: Incidence of invasive pneumococcal disease among HIV-infected 13 
children aged <1 and 1–4 years was 1022 (95% CI 923–1123) per 100,000 and 198 (95% CI 14 
178–220) per 100,000 respectively in 2008.89 The incidence of pneumococcus-associated 15 
lower respiratory tract infection among HIV-exposed uninfected children was 109 (95% CI 16 
47–214) per 100,000 and 629 (95% CI 130–1838) per 100,000 among HIV-infected children.86 17 
Ásbjörnsdóttir et al. reported the incidence of pneumonia among Kenyan HIV-exposed 18 
uninfected infants to be 900 (95% CI 800–1000) per 1,000 child-years.81 Nunes et al. reported 19 
the incidence of invasive pneumococcal disease to be 1509 (95% CI 1350 – 1680) per 100,000 20 
during early (HAART) and  742 (95% CI 644 – 851) during established-HAART eras for less 21 
than 18-year old South Africans.87  22 
Pertussis: The incidence of pertussis among Zambian HIV-exposed infants was reported to be 23 
3.7 (95% CI 0.9–10.1) per 1000 person-months75 while Soofie et al. reported the incidence to 24 
be 2.9 (95% CI 1.8 – 4.5) per 1,000 child-years.78 25 
 26 
 27 
 28 
 29 
 30 
Figure 2: Forest plot of studies with data on incidence rates of tuberculosis in HIV-exposed children  31 
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 32 
Prevalence  33 
Twenty-one TB prevalence studies were pooled together and reported estimated prevalence of 34 
16% (95% CI 12 - 19, I2 = 99%). For studies conducted within the period 1991-2000, the 35 
prevalence was 13% (95% CI 8 - 18)40,43; lower in 2001-2010 with an estimate of 8% (95% CI 36 
5 - 11, I2 = 96%)22,33,37,38,51 and recorded the highest prevalence in recent years with 15% (95% 37 
CI 8 - 22, I2 = 99)15,16,18,19,21,23,27,29,31,41,45,46,52,57 (Figure 3). Fourteen prevalence studies on 38 
hepatitis B (HBV) infection in HIV-infected children were pooled together with an estimate 39 
prevalence of 5% (95% CI 4 - 7, I2 = 90%). Studies conducted between 2001 and 2010 had a 40 
prevalence of 3% (95% CI 2 - 5) 67,68 and 4% (95% CI 3 – 6) between 2011 and 2018 61,63,64,65-41 
72,74 (Figure 4). 42 
The pooled prevalence for pneumococcal infections was 2% (95% CI 1 – 4). There has been a 43 
reduction in prevalence from 9% (95% CI 5 - 14)83 in 1996 to 1% (95% CI 0 – 5)84 in 2001. 44 
Pooled prevalence for pertussis was 3% (95% CI 2 - 4)14,78 while measles was 6% (95% CI 2 45 
– 10).75,76 Two rotavirus diarrhoea prevalence studies were pooled together and reported an 46 
estimated prevalence of 13% (95% CI 8 - 17, I2 = 0%).79,80  47 
 48 
 49 
Figure 3: Forest plot of studies with data on the prevalence of tuberculosis in HIV-infected children 50 
 51 
 52 
Figure 4: Forest plot of studies with data on the prevalence of hepatitis B virus infection in HIV-infected 53 
and HIV-exposed children 54 
 55 
Trend in incidence and prevalence  56 
We analysed the trend in TB incidence with respect to publication years. The trend was non-57 
linear with a downtrend from 2000 to 2010 (at -12.5% per year) and a reduced downward trend 58 
from 2011 to 2018 (at -1.5 per year) as shown in Figure 5. The trend in HBV prevalence was 59 
also analysed. The trend was not linear. There was evidence of a downtrend from 2000 to 2010 60 
(at -4.7% per year) and (at -5.3% per year) from 2011 to 2018 as shown in Figure 6. The TB 61 
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prevalence trend was also non-linear. There was evidence of initial downtrend from 2000 to 62 
2010 (at -3.2% per year) and upward trend from 2011 to 2018 (at +32.7 per year). 63 
 64 
Figure 5: Trends in the incidence of tuberculosis in HIV-infected and exposed children with respect to 65 
publication years 66 
 67 
 68 
 69 
 70 
Figure 6: Trends in the prevalence of hepatitis B virus infection in HIV-infected and exposed children with 71 
respect to publication years 72 
 73 
Case-fatality rates 74 
Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% (95% CI: 13 75 
- 20, I2 = 95%) which translates to 17% of all TB cases dying from the disease. Subgroup 76 
analysis shows the CFR was 18% (95% CI 6 – 24)47 in the 1991-2000 period, 6% (17 – 38, I2 77 
= 95%)33,35-37,48,49,53,54,56,59 in 2001-2010 and 13%  (95% CI 9 – 17, I2 = 96%)15,16,18,20,23-78 
25,30,34,39,44,46,47,50,55,56 in 2011 – 2018. Four studies were pooled for pneumococcal infections 79 
CFRs in HIV-infected and exposed children with a resultant rate of 15% (95% CI 4 – 26, I2 = 80 
95%).81,84,85,90 One study shows that pertussis has CFRs of 13% (95% CI 2 – 38)78 and for 81 
measles the CFR was 1% (95% CI 0 - 4).76  82 
 83 
 84 
Publication bias assessment 85 
Funnel-plot analyses of studies reporting on the prevalence of TB revealed nil significant 86 
publication bias, with the P value for the Begg’s test being 0.185 while the studies assessing 87 
the prevalence of HBV infection showed significant Begg’s test with P value of 0.001 (Figure 88 
7 and 8). Likewise, studies assessing the CFR of TB demonstrated no significant publication 89 
bias Begg’s test P = 0.385 (Figure 9).  90 
 91 
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Figure 7: Funnel plot of studies reporting on the prevalence of tuberculosis in HIV-infected children  93 
 94 
Figure 8: Funnel plot of studies reporting on the prevalence of hepatitis B virus infection in HIV-infected 95 
children 96 
 97 
 98 
Figure 9: Funnel plot of studies reporting on the case-fatality rate of tuberculosis in HIV-infected 99 
children 100 
 101 
 102 
Discussion 103 
This study provides a comprehensive overview of the incidence rate, prevalence and case 104 
fatality rates of different vaccine-preventable diseases in HIV-infected and HIV-exposed 105 
children in sub-Saharan African countries. The review shows that TB is the most researched 106 
vaccine-preventable disease in HIV-infected children in various African countries and settings. 107 
This is not surprising because of the relationship between TB and HIV infection with respect 108 
to the high susceptibility of TB in HIV-infected individuals,91,92 Other vaccine-preventable 109 
diseases like HBV infection, pneumococcal infection, measles, rotavirus gastroenteritis, 110 
pertussis and Hib infections were also studied in several African countries. Important vaccine-111 
preventable diseases such as poliomyelitis, diphtheria, tetanus and yellow fever had no eligible 112 
studies for inclusion revealing the dearth of incidence and prevalence studies on these diseases. 113 
The pooled incidence, prevalence and CFRs reveal there are still high burdens of several 114 
vaccine-preventable diseases in sub-Saharan Africa. 115 
 116 
According to WHO, the global incidence of TB has been reducing at an average of 2 percent 117 
per year.91 TB incidence has declined in the African region by 4 percent annually since 2013.91 118 
Southern African countries with the highest prevalence and incidence of HIV such as South 119 
Africa, Lesotho, Zimbabwe, Eswatini, Namibia and Zambia had remarkable reductions in TB 120 
incidence.91 Our study shows that TB incidence reduced over time, however, the event per 121 
child-year is still high when compared with the End TB strategy goals.93 The World Health 122 
Assembly adopted the resolution known as “End TB strategy goals” which is about the global 123 
strategy and targets for tuberculosis prevention, care and control after 201593. In spite of the 124 
reduction in TB incidence among children, there are still cases of high incidence in certain 125 
countries bearing in mind that many countries in African countries are classified as high-126 
burden.96 A retrospective cohort study in a very high TB/HIV prevalent region in Nigeria 127 
showed a high incidence rate of 21.2/100 per year among children within six months of ART 128 
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enrollment at a period when others were recording much lower incidence.18 TB prevalence has 129 
fluctuated over time with about 15% of HIV-infected children having the disease at a given 130 
point in time.  As of 2017, it was estimated that the global CFR was 16% with many African 131 
countries recording more than 20%.91 This rate is also far higher than the End TB Strategy 132 
milestone of 10% by 2020. 133 
 134 
The pooled HBV infection prevalence among HIV-infected children was 5%, however, a study 135 
done in Rwanda in 2010 revealed a seroprevalence of 16%.68 Ott et al. showed that sub-Saharan 136 
Africa had the highest HBV burden with West African countries having up to 12% hepatitis B 137 
surface antigen prevalence among children and adolescents in the 1990s.94 There has been a 138 
reduction within the region largely due to immunisation programmes, however, there is high 139 
endemicity in some areas. A systematic review of HBV prevalence in Nigeria from studies 140 
conducted from 2000 to 2013 shows that HBV infection ranged from 0.5% to 46.8% with the 141 
pooled prevalence estimate for Nigeria being 13.6%.95  142 
 143 
Our finding shows that the seroprevalence of rotavirus gastroenteritis among African HIV-144 
infected children was 14% although with a small number of included studies. The incidence 145 
and CFR of diarrhoea and pneumonia are much higher in low-income than in high-income 146 
countries and this is reflected in many African and southeast Asian countries having the highest 147 
burden of the diseases.96 The African region has the highest incidence and total death secondary 148 
to diarrhoea and pneumonia with rotavirus and Streptococcus pneumoniae being the 149 
commonest culprits.96 Studies have shown that there is still a persistently high incidence of 150 
some vaccine-preventable diseases in HIV-infected individuals than non-exposed ones even 151 
after the introduction of highly active antiretroviral therapy.97 The incidence of pertussis is also 152 
higher in HIV-exposed and infected children, however, this decreases as the number of vaccine 153 
doses uptake increases.98 154 
 155 
Many African countries with high burdens of HIV are critically lagging in terms of 156 
antiretroviral treatment coverage for HIV-infected children.99 Sub-optimal ART coverage in 157 
children will lead to viral load increase, immunosuppression, etc. and a subsequent high burden 158 
of various vaccine-preventable diseases. Vaccination coverage in many African countries is 159 
still below the expected target.100 As of 2017, the average coverage of third-dose pentavalent 160 
vaccine was 80% while the first dose of measles vaccine in the Global Alliance for Vaccines 161 
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and Immunisation (Gavi)-supported countries was 78%.100 The average coverage of Gavi-162 
funded vaccines in supported countries progressed from 37% in 2016 to 41% in 2017. 163 
 164 
. Use of vaccines has been established to be a beneficial healthcare intervention targeted in 165 
protecting children and adolescents from various vaccine-preventable diseases. Low uptake of 166 
vaccines by African children exposes them to more diseases than children in other regions. It 167 
has also been  established that HIV-infected children are more susceptible to vaccine-168 
preventable diseases such as TB, pneumonia, viral hepatitis etc.101,102 Vaccination is therefore 169 
essential in HIV-infected patients because of the increased risk of developing various infectious 170 
diseases due to their defective immune systems. Studies have also shown that there are poor 171 
immune responses to primary vaccination among HIV-infected children in comparison to HIV-172 
unexposed and HIV-exposed children. The poor immune response among HIV-infected 173 
children may require booster doses for optimal immunity against vaccine-preventable 174 
diseases.103,104 175 
 176 
This review revealed research inequalities across the African region regarding studies on the 177 
burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children. South 178 
Africa contributed about half of the included articles with Nigeria and Kenya following with 179 
fewer studies. This finding is not different from an earlier study looking at the distribution of 180 
epidemiological studies across Africa.105 Some of the Eastern and Southern African countries 181 
with high HIV prevalence had at least an article included in this study, however, West African 182 
countries only had publications from Nigeria and Cote d’Ivoire. 183 
 184 
To the best of our knowledge, this is the first systematic review that addressed the need for 185 
knowing the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed 186 
children in sub-Saharan Africa. Knowledge gap concerning the burden of vaccine-preventable 187 
diseases will impact negatively on the advocacy endeavours targeted at improving vaccination 188 
and vaccine-preventable diseases control efforts in Africa. Healthcare workers and 189 
policymakers need to have a good idea of the burden of different diseases to allocate resources 190 
and facilitate optimal vaccination coverage.  191 
 192 
Recommendations 193 
This review has shown that TB is one of the most important vaccine-preventable diseases in 194 
Africa with the BCG vaccine conferring protection against severe forms of the disease. 195 
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However, the same vaccine is contraindicated in immunocompromised children who ironically 196 
are susceptible to the disease.13 The dilemma of BCG use in HIV-exposed children warrants 197 
the call for newer and safer vaccines against TB especially in HIV-infected children. African 198 
governments and other supporting agencies should ensure that every child has access to routine 199 
childhood vaccines. Issues of under-vaccination and vaccine hesitancy should be adequately 200 
tackled to ensure better vaccine uptake and reduction in the burden of vaccine-preventable 201 
diseases.  202 
 203 
The research capacity of African clinicians, researchers and health administrators should be 204 
built up for them to conduct basic epidemiological research such as incidence, prevalence, 205 
mortality and CFR among HIV-exposed children in various health facilities and communities. 206 
Researchers should be encouraged to disseminate their findings to their immediate 207 
communities and Departments of Health and to publish their findings in peer-reviewed 208 
journals. Established research groups such as Global Burden of Diseases Network should 209 
include the burden of vaccine-preventable diseases in HIV-exposed and non-exposed children 210 
as part of their regular or annual publications. Other African countries should emulate South 211 
Africa in increasing their research activities and outputs with respect to HIV-exposed children. 212 
 213 
There is a need to advocate for an equitable share of healthcare budgeting and finance at every 214 
level of governance in African countries. This will help in ensuring that there is a fair share of 215 
resources for preventive and treatment services such as vaccination and antiretroviral therapy 216 
for HIV-exposed children. African countries should, as a matter of urgency, complete the 217 
introduction of newer and important vaccines such as rotavirus vaccine, Hib vaccine and 218 
pneumococcal vaccine. These should be included as part of their current national immunisation 219 
programme schedule.95 According to WHO, the global coverage for both pneumococcal 220 
vaccine and rotavirus vaccines were as little as 44 percent and 25 percent respectively.100 221 
African countries should be supported in developing vaccine procurement budgets, 222 
procurement practices, and capacity development for vaccine planning and advocacy.106 223 
 224 
Study limitations 225 
This study was limited by several factors beyond the reviewers’ control. We planned to review 226 
all the vaccine-preventable diseases associated with vaccines included in the national 227 
immunisation programme schedule in sub-Saharan Africa, however, we could not find articles 228 
that met the eligibility criteria for some of the diseases. Secondly, there was high heterogeneity 229 
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even with sub-group analysis between included studies, which implies the possibility of other 230 
contributory factors associated with the diseases. Some of the studies did not include relevant 231 
information such as antiretroviral coverage, CD4 count, viral load, vaccination status and other 232 
contributory factors. Thirdly, we could not include many studies because the diagnostic criteria 233 
for different vaccine-preventable diseases were not specified and clearly defined.  234 
 235 
Furthermore, the presence of various limitations did not stop us from making some meaningful 236 
conclusions from this study. This review gives a clearer picture of the burden and trend of TB 237 
and able to have insights about the burden of other diseases as well despite having a small 238 
number of studies included in this review. African investigators should as a matter of priority 239 
have proper diagnostic criteria and documentation for diseases for all HIV-infected and HIV-240 
exposed children treated at the health facilities across the region. Key parameters such as CD4 241 
counts, vaccination status etc. should be included in future studies. 242 
 243 
Conclusions 244 
This systematic review and meta-analysis provide an all-inclusive analysis of the incidence 245 
rates, prevalence and CFR of various vaccine-preventable diseases. This study shows that some 246 
vaccine-preventable diseases still have high incidence, prevalence and CFRs in HIV-infected 247 
and HIV-exposed children. There was also the dearth of research activities on vaccine-248 
preventable disease studies concerning HIV-infected and HIV-exposed uninfected children in 249 
many African countries. The findings are useful in advocating for a more equitable share of 250 
healthcare financing especially for preventive services such as vaccination of both HIV-251 
exposed and non-exposed children to reduce the burden of vaccine-preventable diseases.  252 
 253 
 254 
Methods and design 255 
This systematic review was developed in line with the Preferred Reporting Items for Systematic 256 
Review and Meta-Analysis (PRISMA) 2015 statement.107 The review was registered with 257 
PROSPERO (International prospective register of systematic reviews) (CRD42018095341). 258 
Inclusion criteria 259 
Type of participants: The review included sub-Saharan African children who are HIV-infected 260 
or HIV-exposed and aged <18 years old. 261 
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Types of outcome:  262 
We included studies that reported the incidence, prevalence and case-fatality rates (CFR) as 263 
outcomes in HIV-infected and HIV-exposed children. 264 
Primary outcomes 265 
Prevalence was defined as proportions of all individuals suspected of having specific vaccine-266 
preventable diseases with confirmed laboratory diagnosis or proportions of individuals 267 
fulfilling clinical case definition for specific vaccine-preventable diseases. Incidence was 268 
defined as the number of new cases of different vaccine-preventable diseases that occur during 269 
a given period in the defined population. 270 
We also determined the trend in the incidence and/or prevalence of vaccine-preventable 271 
diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 272 
2018. 273 
Secondary outcomes 274 
We included CFRs associated with vaccine-preventable diseases. Case fatality was described 275 
as mortality among confirmed or probable cases for a specific vaccine-preventable disease. 276 
Type of studies: The review included cohort studies, case-control studies, cross-sectional 277 
studies and other observational studies. We planned to include studies that involved any of 278 
the following vaccine-preventable diseases: 279 
i. Tuberculosis  280 
ii. Poliomyelitis 281 
iii. Hepatitis B virus infection  282 
iv. Rotavirus gastroenteritis 283 
v. Diphtheria 284 
vi. Tetanus 285 
vii. Pertussis 286 
viii. Pneumococcal diseases 287 
ix. Measles  288 
x. Rubella 289 
xi. Yellow fever 290 
 291 
Exclusion criteria 292 
 Intervention studies 293 
 Unclear diagnostic criteria 294 
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 295 
Search strategy methods for the identification of studies 296 
A comprehensive search strategy was developed to identify relevant studies up to August 2018, 297 
regardless of publication status or language. Scopus, Web of Science, MEDLINE via PubMed 298 
and CINAHL were searched for relevant publications. The search process was complemented 299 
by reviewing citations of all identified eligible studies. We also searched relevant World Health 300 
Organization position papers and documents on vaccines. (See Appendix for PubMed search 301 
strategy).  302 
Selection of eligible studies 303 
Two of the authors, (OOA and AA) screened the search results using the abstract titles. They 304 
also independently went through the full text of potential studies to assess whether they met 305 
the required inclusion criteria. Non-human studies, reviews, intervention studies, letters, 306 
commentaries and editorials were excluded. Studies not written in English, French, German, 307 
Spanish, Portuguese or Dutch were excluded. We resolved disagreements by consensus.  308 
Data collection process 309 
The two authors then extracted data from text, tables and figures. The data were recorded on a 310 
standardised form. We planned to contact authors of included studies in case of unclear or 311 
missing data.                                  312 
The following data were extracted from selected studies: 313 
 Study characteristics including period and design. 314 
 Vaccine-preventable diseases patient characteristics such as age and HIV status.  315 
 Prevalence or incidence of vaccine-preventable diseases: confirmed cases and cases 316 
meeting the clinical definition. 317 
 Diagnostic methods: laboratory methods and clinical case definitions. 318 
 Death attributed to vaccine-preventable diseases. 319 
Risk of bias in individual studies 320 
The risk of bias and quality of the included studies were assessed with the Newcastle-Ottawa 321 
Quality Scale.108 The criteria assessed included the following (1) selection of participants, (2) 322 
comparability, (3) exposure, and (4) outcome.  323 
 324 
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Data synthesis 325 
OOA summarised the incidence and prevalence of various vaccine-preventable diseases. 326 
Where possible, incidence and prevalence data from each of the included studies were 327 
combined by random effects meta-analysis in accordance with the Mantel-Haenszel method. 328 
Heterogeneity was evaluated using the Chi-squared test of homogeneity (significant for P < 329 
0.1) and quantified using the I-squared statistic (>50% substantial heterogeneity).109 Subgroup 330 
analyses were conducted in cases with substantial heterogeneity. Subgroup analysis was 331 
conducted using the following variables: period of study (1991- 2000, 2001-2010 and 2011 – 332 
2018). We also used funnel plot regression to assess publication bias. STATA software version 333 
14.0 (STATA Corporation, College Station, TX, USA) was used to do all calculations, the 334 
meta-analysis and generate forest plots.110 335 
Additional analyses: Trend analysis 336 
We examined time trends in the incidence and prevalence of vaccine-preventable diseases 337 
estimates using Poisson regression models with the prevalence estimates as the outcome 338 
variable and the calendar year of the publication as the predictor. This method allows for 339 
estimation of time trends across individual calendar years to obtain average annual percentage 340 
change (AAPC), if the rate of change is at a constant rate of the previous year. 111 The Poisson 341 
regression procedure fits a model of the following form: 342 
                             
  0 1log log( )yprevalence b b y sample size                                (1) 343 
where ‘cases’ equal prevalence estimates reported per year, log is the natural log, b0 is the 344 
intercept, b1 is the trend, y is the year – given as 0, 1, 2, … 18 (year 0 is 1970, year 1 is 1971, 345 
and so on to 2014), and log of ‘sample size’ was entered as the offset. The AAPC was calculated 346 
using the following formula: 347 
                                             
 1 1 100bAAPC e  
                                                (2) 348 
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Abstract 32 
There are knowledge gaps regarding evidence-based research on the burden of vaccine-33 
preventable diseases among human immunodeficiency virus (HIV)-infected and HIV-exposed 34 
children aged <18years in sub-Saharan Africa. It is therefore essential to determine the trend and 35 
burden of vaccine-preventable diseases. We completed a systematic review and meta-analysis to 36 
identify the incidence, prevalence and case-fatality rates (CFR) attributed to various vaccine-37 
preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa. The 38 
trends in the prevalence of vaccine-preventable diseases among HIV-infected and HIV-exposed 39 
children were also determined. Nine studies on tuberculosis (TB) were pooled to give an overall 40 
incidence rate estimate of 60 (95% confidence interval [CI] 30 – 70) per 1,000 child-years. The 41 
incidence of pneumococcal infections varied between 109-1509 per 100,000 while pertussis was 42 
between 2.9 and 3.7 per 1000 child-year. Twenty-two TB prevalence studies reported an estimated 43 
prevalence of 16%. Fifteen prevalence studies on hepatitis B infection were pooled together with 44 
an estimated prevalence of 5%. The pooled prevalence for pneumococcal infections was 2% while 45 
rotavirus diarrhoea reported a prevalence of 13%. Twenty-nine studies on TB were pooled to give 46 
an overall CFR estimate of 17% while pneumococcal infections in HIV-infected and exposed 47 
children were pooled together with a resultant rate of 15%. Some of the vaccine-preventable 48 
diseases still have high incidences, prevalence and CFR among HIV-infected and HIV-exposed 49 
children. There is also a dearth of research data on the burden of several vaccine-preventable 50 
diseases among HIV-infected and exposed children and a need for more studies in this area.  51 
Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; burden 52 
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 59 
Background 60 
Human immunodeficiency virus (HIV) infection remains a leading public-health challenge and a 61 
principal cause of the infectious disease burden in low- and middle-income countries especially in 62 
sub-Saharan Africa.1 This region accounts for the bulk of HIV infection with about 36.7 million 63 
people living with the disease an estimated 75% of the global burden.2,3 It was also estimated that 64 
approximately 2.1 million children aged under 15 years were living with HIV with the majority 65 
coming from sub-Saharan Africa and about 31% having access to antiretroviral therapy in 2014.4 66 
The incidence of HIV infections among children declined in 2014 but there were still 220,000 new 67 
infections that year alone.4 HIV-infected children have an increased risk of developing various 68 
vaccine-preventable diseases due to their defective immune systems.5 This makes it crucial to 69 
focus on the vaccination of HIV-infected and exposed children. The majority of these children are 70 
also residents of low-and-middle-income countries characterised by limited access to HIV 71 
diagnosis, treatment and care.2  72 
Vaccination against various vaccine-preventable diseases has been proven to be a beneficial and 73 
cost-effective public-health measure for protecting children, adolescents and adults from these 74 
diseases, thereby reducing the morbidity and mortality attributable to them.6,7 Coverage of routine 75 
vaccinations is still low in some developing countries and not sufficient to meet the Global Vaccine 76 
Action Plan (GVAP) targets.8–10 Some African countries have low or decreasing immunisation 77 
coverage over the years with some not achieving ≥ 90% national coverage for vaccines included 78 
in their national immunisation schedule by the World Health Organization (WHO) in 2016.11 Sub-79 
Saharan African countries account for about 34% of the global vaccine-preventable diseases 80 
burden, and are also responsible for the highest proportion of under-five mortality from these 81 
diseases.12   82 
Recently, most developing countries have included routine childhood vaccines such as hepatitis 83 
B; Bacillus Calmette–Guérin (BCG); diphtheria, tetanus and pertussis (DTP); Haemophilus 84 
influenzae type b (Hib); polio; pneumococcal conjugate; measles; rotavirus (RV), rubella and 85 
yellow fever vaccines in their national Expanded Programme on Immunisation (EPI).13 These 86 
vaccines also protect against diseases such as tuberculosis, poliomyelitis, rotavirus gastroenteritis, 87 
diphtheria, tetanus, pertussis, pneumococcal diseases, hepatitis B infection, rubella, measles and 88 
yellow fever.  89 
The gap in knowledge, especially in terms of evidence-based research, on the burden of vaccine-90 
preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa, 91 
warrants this study.14 This study completed a systematic review of literature and meta-analysis to 92 
identify the incidence, prevalence and mortality due to various vaccine-preventable diseases 93 
among HIV-infected and HIV-exposed children in sub-Saharan Africa since the advent of HIV in 94 
the 1980s. This study is essential in determining the trend and current burden of vaccine-95 
preventable disease epidemiology in sub-Saharan Africa.  96 
 97 
Objectives 98 
Primary objectives 99 
1. To appraise all available published literature on the incidence and prevalence of vaccine-100 
preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, 101 
rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles, 102 
rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan 103 
Africa.  104 
2. To determine the trend in the incidence and/or prevalence of vaccine-preventable diseases 105 
such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, 106 
diphtheria, tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever 107 
among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 2018. 108 
Secondary objective 109 
1. To describe the case-fatality rate ascribed to vaccine-preventable diseases such as 110 
tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, 111 
tetanus, pertussis, pneumococcal diseases, measles, rubella and yellow fever among HIV-112 
infected and HIV-exposed children in sub-Saharan Africa. 113 
 114 
Results 115 
 116 
Literature search and result 117 
Figure 1 shows the study selection process reported in line with PRISMA guidelines. We identified 118 
3430 publications through the search of different databases. We also identified 13 additional 119 
articles through the screening of reference lists of various related articles. We screened 188 full-120 
text articles and selected 76 articles for inclusion in the review and 70 articles were suitable for 121 
the meta-analysis (Figure 1). 122 
Study characteristics 123 
Table 1 provides a summary of the included studies and the vaccine-preventable diseases of 124 
interest.  The table shows that 45 articles reported on tuberculosis, 14 on hepatitis B virus infection, 125 
ten studies focused on pneumococcal infections, two on rotavirus gastroenteritis, three on measles 126 
and three on pertussis. The included articles consist of 41 cross-sectional studies, 31 cohort studies, 127 
four case-control studies and one time-series analysis.  128 
South Africa had the highest number of published articles with 35 articles, Nigeria produced 10 129 
articles, four were from Kenya, four from Ethiopia and two studies were conducted in multiple 130 
countries. The other studies were conducted in Rwanda, Tanzania, Cote d' Ivoire, Uganda, Malawi, 131 
Botswana, Zimbabwe, Zambia, Mozambique and Swaziland (Table 1). A total of 46,882 children 132 
were included in this review.  HIV-infected children were included in 71 studies while two studies 133 
had both HIV-infected and HIV-exposed uninfected children, and one study with only HIV-134 
exposed children. The included studies were conducted between 1992 and 2016. 135 
Using the Newcastle-Ottawa Quality Scale for the quality assessment of the eligible studies, 11 136 
articles scored eight points; 15 articles scored seven points; 27 articles scored six points; 15 articles 137 
scored five points; seven articles scored four points and two articles scored three points. The 138 
characteristics of the eligible studies are summarised in Table 1. 139 
 140 
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Figure 1: Flow diagram of the selection process 171 
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 Table 1: Characteristics of the study population 
First author and year Study period Study design Country Sample size  VPD Outcomes HIV 
status 
Quality 
scores 
Abuogi 201315 2009 - 2010 Cohort Kenya 689 Tuberculosis C, I, P HI 7 
Adams 201416 2006 - 2012 Cross-sectional Tanzania 1193 Tuberculosis C, P HI 4 
Alemu 201617 2009 - 2014 Cohort Ethiopia 645 Tuberculosis I HI 6 
Anigilaje 201618 2010 - 2013 Cohort  Nigeria 368 Tuberculosis P HI 8 
Auld 201419 2004 - 2008 Cohort  Cote d' Ivoire 2110 Tuberculosis I, P HI 8 
Bakeera 201120 2003 - 2006 Cohort  Uganda 1806 Tuberculosis I, C HI 8 
Bonnet 201821 2012 - 2014 Cohort Uganda 113 Tuberculosis C HI 7 
Braitstein 200922 2001 - 2007 Cohort Kenya 6,535 Tuberculosis I, P HI 8 
Buck 201323 2010 Cohort Malawi 4874 Tuberculosis C, P HI 8 
Carlucci 201724 2012 - 2014 Cohort  Multiple  386 Tuberculosis C HI 8 
Cavanaugh 201225 2006 - 2007 Cross-sectional Kenya 323 Tuberculosis C HI 6 
Chaya 201626 2006 - 2011 Cross-sectional South Africa 47 Tuberculosis I  HI 6 
Cruz 201527 NR Cohort Botswana 100 Tuberculosis P HI 6 
Dangor 201328 2005 - 2009 Time-series analysis South Africa 1985 Tuberculosis I HI 7 
De Maayar 201129 NR Cross-sectional South Africa 58 Tuberculosis P HI 7 
Ebonyi 201630 2005 - 2013 Cohort  Nigeria 260 Tuberculosis C HI 8 
Ebonyi 2016b31 2005-2012 Cohort  Nigeria 876 Tuberculosis P HI 8 
Elenga 200532 2000-2003 Cohort Cote d' Ivoire 282 Tuberculosis I HI 8 
Ferrand 201033 2007-2008 Cross-sectional Zimbabwe 139 Tuberculosis P HI 7 
Hall 201734 2005-2008 Cohort South Africa 224 Tuberculosis C HI 8 
Hesseling 2009a35 2004-2006 Cross-sectional  South Africa 3321 Tuberculosis C HI 6 
Hesseling 200536 1992-2000 Cohort South Africa 93 Tuberculosis C HI 8 
Hesseling 200637 2002-2005 Cohort South Africa 108 Tuberculosis C, P HI 7 
Hesseling 2009b38 2004-2006 Cross-sectional South Africa 3321 Tuberculosis I, P HI 7 
Hicks 201439 2009-2010 Cohort  South Africa 64 Tuberculosis C HI 6 
Jeena 200040 1995-1998 Cross-sectional  South Africa 27 Tuberculosis P HI 5 
Kasambira 201141 2006-2009 Cross-sectional  South Africa 270 Tuberculosis P HI 6 
Madhi 2000b42 1996-1997 Cross-sectional South Africa 67 Tuberculosis C HI 5 
Meyers 200043 1996 Cross-sectional South Africa 144 Tuberculosis P HI 5 
Mwangwa 201744 2012-2013 Cohort Multiple  17 Tuberculosis C HI 7 
Obiagwu 201345 2010 Cross-sectional Nigeria 22 
Tuberculosis, 
Measles P HI 
6 
Okechukwu 201146 2007-2008 Cross-sectional Nigeria 210 Tuberculosis C, P HI 6 
Osman 201747 2005-2012 Cohort South Africa 3143 Tuberculosis C HI 6 
Padayatchi 200648 1993-2002 Cross-sectional South Africa 6 Tuberculosis C HI 5 
Palme 200249 1995-1997 Cohort Ethiopia 58 Tuberculosis C HI 6 
Patel 201350 2007-2009 Cohort Congo DRC 31 Tuberculosis C HI 7 
Robinson 200751 1999-2001 Case-control South Africa 47 Tuberculosis P HI 6 
Rose 201252 2008-2010 Cohort Tanzania 54 Tuberculosis P HI 6 
Schaaf 200753 2003-2005 Cross-sectional South Africa 133 Tuberculosis C HI 5 
Soeters 200554 2000-2001 Cross-sectional South Africa 43 Tuberculosis C HI 4 
Walters 201455 2003-2010 Cohort South Africa 494 Tuberculosis C HI 6 
Walters 200856 2003-2005 Cross-sectional South Africa 137 Tuberculosis C HI 6 
Westerlund 201457 2003-2008 Cohort Ethiopia 138 Tuberculosis P HI 7 
Wiseman 201158 2004-2006 Cross-sectional South Africa 52 Tuberculosis C HI 5 
Yotebieng 201059 2004-2008 Cohort South Africa 573 Tuberculosis C HI 6 
Kouakoussui 200460 2003 Cohort Cote d’Ivoire 270 Tuberculosis I HI 7 
Abera 201461 2014 Cross-sectional Ethiopia 253 HBV infection P HI 6 
Ashir 200962 2007 Case-control Nigeria 284 HBV infection P HI 5 
Beghin 201763 2014 Cross-sectional South Africa 183 HBV infection P HI 6 
Chotun 201564 2011 - 2012 Cross-sectional  South Africa 1000 HBV infection P HE 6 
Uleanya 201665 NR Cross-sectional Nigeria 140 HBV infection P HI 4 
Dziuban 201366 2009 - 2011 Cross-sectional Swaziland 500 HBV infection P HI 3 
Ikpeme 201367 2010-2011 Cross-sectional Nigeria 166 HBV infection P HI 4 
Jooste 201668 2015-2016 Cohort South Africa 625 HBV infection P HI 7 
Muro 201369 2006-2008 Cross-sectional Tanzania 157 HBV infection P HI 5 
Mutwa 201370 2010 Cohort Rwanda 88 HBV infection P HI 7 
Nwolisa 201371 2010 Cross-sectional Nigeria 139 HBV infection P HI 4 
Sadoh 201172 NR Cross-sectional Nigeria 155 HBV infection P HI 5 
Telatela 200773 2006 Cross-sectional Tanzania 167 HBV infection P HI 4 
Varo 201674 2008-2010 Cross-sectional Malawi 91 HBV infection P HI 3 
Moss 200275 1998-2000 Cross-sectional Zambia 93 Measles P HI 6 
Wirth 201576 2009-2010 Case-control Botswana 189 Measles C HI 5 
du Plessis 201814 2013 - 2015 Cross-sectional South Africa 300 Pertussis  P HI 6 
Gill 201677 2015 Cohort Zambia 347 Pertussis I HI 7 
Soofie 201678 2015 Cross-sectional South Africa 599 Pertussis C, I, P HE 5 
Johnson 200079 1996-1997 Cross-sectional South Africa 31 
Rotavirus 
gastroenteritis P HI 
6 
Moyo 201480 2010-2011 Case-control Tanzania 26 
Rotavirus 
gastroenteritis P HI 
5 
Asbjörnsdóttir 201381 
1999-2002 Cohort Kenya 
388 
Pneumococcal 
infection C,I HI 
6 
Nathoo 199682 1993-1994 Cohort Zimbabwe 168 
Pneumococcal 
infection P HI 
7 
Zar 200183 1998 Cross-sectional South Africa 151 
Pneumococcal 
infection P HI 
6 
Jones 199884 1996 Cross-sectional South Africa 25 
Pneumococcal 
infection C HI 
5 
Roca 201085 2004-2006 Cross-sectional Mozambique 54 
Pneumococcal 
infection C HI 
6 
Cohen 201686 2009 - 2013 Cross-sectional South Africa 211 
Pneumococcal 
infection I HEU,HI 
4 
Nunes 201187 2003-2008 Cross-sectional South Africa 938 
Pneumococcal 
infection I HI 
6 
von Mollendorf 2017a88 2009–2013 Cross-sectional South Africa 495 
Pneumococcal 
infection C, I HI 
5 
von Gottberg 201389 2003-2008 Cross-sectional  South Africa 1749 
Pneumococcal 
infection I HI 
5 
Nyasulu 201190 2003-2005 Cross-sectional South Africa 1124 
Pneumococcal 
infection C HI 
6 
  
NR- Not recorded; C- Case-fatality rate; I – Incidence; P – Prevalence; Hib- Haemophilus influenzae type b; HI- HIV-infected; HE- HIV-exposed; HEU – HIV-exposed uninfected; VPD - vaccine–
preventable diseases. 
 1 
Incidence rates  2 
Tuberculosis: Nine studies15,17-20,22,32,35 on TB were pooled to give an overall incidence rate 3 
estimate of 60 (95% CI 30 – 70) per 1,000 child-years at risk for tuberculosis based on a 4 
random-effects model (I2 = 99%; Figure 2). Subgroup analysis established change over time in 5 
incidence rates when comparing studies conducted before and after 2011. The pooled incidence 6 
rates for tuberculosis in those conducted before 2010 was 70 (95% CI -20 - 160) per 1,000 7 
child-years32,35 and 40 (95% CI 20 - 50) per 1,000 child-years in studies conducted between 8 
2011 and 2018.15,17-20,22 The heterogeneity of the TB incidence could not be explained by the 9 
subgroup analysis. Kouakoussui et al. reported TB incidence of 0.71 per 100 child/months 10 
before initiation of highly active antiretroviral therapy (HAART) and 0.16 per 100 11 
child/months during HAART treatment among Ivorian HIV-infected children.60 12 
Pneumococcal infections: Incidence of invasive pneumococcal disease among HIV-infected 13 
children aged <1 and 1–4 years was 1022 (95% CI 923–1123) per 100,000 and 198 (95% CI 14 
178–220) per 100,000 respectively in 2008.89 The incidence of pneumococcus-associated 15 
lower respiratory tract infection among HIV-exposed uninfected children was 109 (95% CI 16 
47–214) per 100,000 and 629 (95% CI 130–1838) per 100,000 among HIV-infected children.86 17 
Ásbjörnsdóttir et al. reported the incidence of pneumonia among Kenyan HIV-exposed 18 
uninfected infants to be 900 (95% CI 800–1000) per 1,000 child-years.81 Nunes et al. reported 19 
the incidence of invasive pneumococcal disease to be 1509 (95% CI 1350 – 1680) per 100,000 20 
during early (HAART) and  742 (95% CI 644 – 851) during established-HAART eras for less 21 
than 18-year old South Africans.87  22 
Pertussis: The incidence of pertussis among Zambian HIV-exposed infants was reported to be 23 
3.7 (95% CI 0.9–10.1) per 1000 person-months75 while Soofie et al. reported the incidence to 24 
be 2.9 (95% CI 1.8 – 4.5) per 1,000 child-years.78 25 
 26 
 27 
 28 
 29 
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 30 
Figure 2: Forest plot of studies with data on incidence rates of tuberculosis in HIV-exposed children  31 
 32 
Prevalence  33 
Twenty-one TB prevalence studies were pooled together and reported estimated prevalence of 34 
16% (95% CI 12 - 19, I2 = 99%). For studies conducted within the period 1991-2000, the 35 
prevalence was 13% (95% CI 8 - 18)40,43; lower in 2001-2010 with an estimate of 8% (95% CI 36 
5 - 11, I2 = 96%)22,33,37,38,51 and recorded the highest prevalence in recent years with 15% (95% 37 
CI 8 - 22, I2 = 99)15,16,18,19,21,23,27,29,31,41,45,46,52,57 (Figure 3). Fourteen prevalence studies on 38 
hepatitis B (HBV) infection in HIV-infected children were pooled together with an estimate 39 
prevalence of 5% (95% CI 4 - 7, I2 = 90%). Studies conducted between 2001 and 2010 had a 40 
prevalence of 3% (95% CI 2 - 5) 67,68 and 4% (95% CI 3 – 6) between 2011 and 2018 61,63,64,65-41 
72,74 (Figure 4). 42 
The pooled prevalence for pneumococcal infections was 2% (95% CI 1 – 4). There has been a 43 
reduction in prevalence from 9% (95% CI 5 - 14)83 in 1996 to 1% (95% CI 0 – 5)84 in 2001. 44 
Pooled prevalence for pertussis was 3% (95% CI 2 - 4)14,78 while measles was 6% (95% CI 2 45 
– 10).75,76 Two rotavirus diarrhoea prevalence studies were pooled together and reported an 46 
estimated prevalence of 13% (95% CI 8 - 17, I2 = 0%).79,80  47 
 48 
 49 
Figure 3: Forest plot of studies with data on the prevalence of tuberculosis in HIV-infected children 50 
 51 
 52 
Figure 4: Forest plot of studies with data on the prevalence of hepatitis B virus infection in HIV-infected 53 
and HIV-exposed children 54 
 55 
Trend in incidence and prevalence  56 
We analysed the trend in TB incidence with respect to publication years. The trend was non-57 
linear with a downtrend from 2000 to 2010 (at -12.5% per year) and a reduced downward trend 58 
from 2011 to 2018 (at -1.5 per year) as shown in Figure 5. The trend in HBV prevalence was 59 
also analysed. The trend was not linear. There was evidence of a downtrend from 2000 to 2010 60 
(at -4.7% per year) and (at -5.3% per year) from 2011 to 2018 as shown in Figure 6. The TB 61 
prevalence trend was also non-linear. There was evidence of initial downtrend from 2000 to 62 
2010 (at -3.2% per year) and upward trend from 2011 to 2018 (at +32.7 per year). 63 
 64 
Figure 5: Trends in the incidence of tuberculosis in HIV-infected and exposed children with respect to 65 
publication years 66 
 67 
 68 
 69 
 70 
Figure 6: Trends in the prevalence of hepatitis B virus infection in HIV-infected and exposed children with 71 
respect to publication years 72 
 73 
Case-fatality rates 74 
Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% (95% CI: 13 75 
- 20, I2 = 95%) which translates to 17% of all TB cases dying from the disease. Subgroup 76 
analysis shows the CFR was 18% (95% CI 6 – 24)47 in the 1991-2000 period, 6% (17 – 38, I2 77 
= 95%)33,35-37,48,49,53,54,56,59 in 2001-2010 and 13%  (95% CI 9 – 17, I2 = 96%)15,16,18,20,23-78 
25,30,34,39,44,46,47,50,55,56 in 2011 – 2018. Four studies were pooled for pneumococcal infections 79 
CFRs in HIV-infected and exposed children with a resultant rate of 15% (95% CI 4 – 26, I2 = 80 
95%).81,84,85,90 One study shows that pertussis has CFRs of 13% (95% CI 2 – 38)78 and for 81 
measles the CFR was 1% (95% CI 0 - 4).76  82 
 83 
 84 
Publication bias assessment 85 
Funnel-plot analyses of studies reporting on the prevalence of TB revealed nil significant 86 
publication bias, with the P value for the Begg’s test being 0.185 while the studies assessing 87 
the prevalence of HBV infection showed significant Begg’s test with P value of 0.001 (Figure 88 
7 and 8). Likewise, studies assessing the CFR of TB demonstrated no significant publication 89 
bias Begg’s test P = 0.385 (Figure 9).  90 
 91 
 92 
Figure 7: Funnel plot of studies reporting on the prevalence of tuberculosis in HIV-infected children  93 
 94 
95 
Figure 8: Funnel plot of studies reporting on the prevalence of hepatitis B virus infection in HIV-infected 96 
children 97 
 98 
 99 
Figure 9: Funnel plot of studies reporting on the case-fatality rate of tuberculosis in HIV-infected 100 
children 101 
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Discussion 104 
This study provides a comprehensive overview of the incidence rate, prevalence and case 105 
fatality rates of different vaccine-preventable diseases in HIV-infected and HIV-exposed 106 
children in sub-Saharan African countries. The review shows that TB is the most researched 107 
vaccine-preventable disease in HIV-infected children in various African countries and settings. 108 
This is not surprising because of the relationship between TB and HIV infection with respect 109 
to the high susceptibility of TB in HIV-infected individuals,91,92 Other vaccine-preventable 110 
diseases like HBV infection, pneumococcal infection, measles, rotavirus gastroenteritis, 111 
pertussis and Hib infections were also studied in several African countries. Important vaccine-112 
preventable diseases such as poliomyelitis, diphtheria, tetanus and yellow fever had no eligible 113 
studies for inclusion revealing the dearth of incidence and prevalence studies on these diseases. 114 
The pooled incidence, prevalence and CFRs reveal there are still high burdens of several 115 
vaccine-preventable diseases in sub-Saharan Africa. 116 
 117 
According to WHO, the global incidence of TB has been reducing at an average of 2 percent 118 
per year.91 TB incidence has declined in the African region by 4 percent annually since 2013.91 119 
Southern African countries with the highest prevalence and incidence of HIV such as South 120 
Africa, Lesotho, Zimbabwe, Eswatini, Namibia and Zambia had remarkable reductions in TB 121 
incidence.91 Our study shows that TB incidence reduced over time, however, the event per 122 
child-year is still high when compared with the End TB strategy goals.93 The World Health 123 
Assembly adopted the resolution known as “End TB strategy goals” which is about the global 124 
strategy and targets for tuberculosis prevention, care and control after 201593. In spite of the 125 
reduction in TB incidence among children, there are still cases of high incidence in certain 126 
countries bearing in mind that many countries in African countries are classified as high-127 
burden.96 A retrospective cohort study in a very high TB/HIV prevalent region in Nigeria 128 
showed a high incidence rate of 21.2/100 per year among children within six months of ART 129 
enrollment at a period when others were recording much lower incidence.18 TB prevalence has 130 
fluctuated over time with about 15% of HIV-infected children having the disease at a given 131 
point in time.  As of 2017, it was estimated that the global CFR was 16% with many African 132 
countries recording more than 20%.91 This rate is also far higher than the End TB Strategy 133 
milestone of 10% by 2020. 134 
 135 
The pooled HBV infection prevalence among HIV-infected children was 5%, however, a study 136 
done in Rwanda in 2010 revealed a seroprevalence of 16%.68 Ott et al. showed that sub-Saharan 137 
Africa had the highest HBV burden with West African countries having up to 12% hepatitis B 138 
surface antigen prevalence among children and adolescents in the 1990s.94 There has been a 139 
reduction within the region largely due to immunisation programmes, however, there is high 140 
endemicity in some areas. A systematic review of HBV prevalence in Nigeria from studies 141 
conducted from 2000 to 2013 shows that HBV infection ranged from 0.5% to 46.8% with the 142 
pooled prevalence estimate for Nigeria being 13.6%.95  143 
 144 
Our finding shows that the seroprevalence of rotavirus gastroenteritis among African HIV-145 
infected children was 14% although with a small number of included studies. The incidence 146 
and CFR of diarrhoea and pneumonia are much higher in low-income than in high-income 147 
countries and this is reflected in many African and southeast Asian countries having the highest 148 
burden of the diseases.96 The African region has the highest incidence and total death secondary 149 
to diarrhoea and pneumonia with rotavirus and Streptococcus pneumoniae being the 150 
commonest culprits.96 Studies have shown that there is still a persistently high incidence of 151 
some vaccine-preventable diseases in HIV-infected individuals than non-exposed ones even 152 
after the introduction of highly active antiretroviral therapy.97 The incidence of pertussis is also 153 
higher in HIV-exposed and infected children, however, this decreases as the number of vaccine 154 
doses uptake increases.98 155 
 156 
Many African countries with high burdens of HIV are critically lagging in terms of 157 
antiretroviral treatment coverage for HIV-infected children.99 Sub-optimal ART coverage in 158 
children will lead to viral load increase, immunosuppression, etc. and a subsequent high burden 159 
of various vaccine-preventable diseases. Vaccination coverage in many African countries is 160 
still below the expected target.100 As of 2017, the average coverage of third-dose pentavalent 161 
vaccine was 80% while the first dose of measles vaccine in the Global Alliance for Vaccines 162 
and Immunisation (Gavi)-supported countries was 78%.100 The average coverage of Gavi-163 
funded vaccines in supported countries progressed from 37% in 2016 to 41% in 2017. 164 
 165 
Low uptake of vaccines by African children exposes them to more diseases than children in 166 
other regions. Use of vaccines has been established to be a beneficial healthcare intervention 167 
targeted in protecting children and adolescents from various vaccine-preventable diseases. Low 168 
uptake of vaccines by African children exposes them to more diseases than children in other 169 
regions. It has also been  established that HIV-infected children are more susceptible to 170 
vaccine-preventable diseases such as TB, pneumonia, viral hepatitis etc.101,102 Vaccination is 171 
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therefore essential in HIV-infected patients because of the increased risk of developing various 172 
infectious diseases due to their defective immune systems. Studies have also shown that there 173 
are poor immune responses to primary vaccination among HIV-infected children in comparison 174 
to HIV-unexposed and HIV-exposed children. The poor immune response among HIV-175 
infected children may require booster doses for optimal immunity against vaccine-preventable 176 
diseases.103,104 177 
 178 
This review revealed research inequalities across the African region regarding studies on the 179 
burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children. South 180 
Africa contributed about half of the included articles with Nigeria and Kenya following with 181 
fewer studies. This finding is not different from an earlier study looking at the distribution of 182 
epidemiological studies across Africa.1051 Some of the Eastern and Southern African countries 183 
with high HIV prevalence had at least an article included in this study, however, West African 184 
countries only had publications from Nigeria and Cote d’Ivoire. 185 
 186 
To the best of our knowledge, this is the first systematic review that addressed the need for 187 
knowing the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed 188 
children in sub-Saharan Africa. Knowledge gap concerning the burden of vaccine-preventable 189 
diseases will impact negatively on the advocacy endeavours targeted at improving vaccination 190 
and vaccine-preventable diseases control efforts in Africa. Healthcare workers and 191 
policymakers need to have a good idea of the burden of different diseases to allocate resources 192 
and facilitate optimal vaccination coverage.  193 
 194 
Recommendations 195 
This review has shown that TB is one of the most important vaccine-preventable diseases in 196 
Africa with the BCG vaccine conferring protection against severe forms of the disease. 197 
However, the same vaccine is contraindicated in immunocompromised children who ironically 198 
are susceptible to the disease.13 The dilemma of BCG use in HIV-exposed children warrants 199 
the call for newer and safer vaccines against TB especially in HIV-infected children. African 200 
governments and other supporting agencies should ensure that every child has access to routine 201 
childhood vaccines. Issues of under-vaccination and vaccine hesitancy should be adequately 202 
tackled to ensure better vaccine uptake and reduction in the burden of vaccine-preventable 203 
diseases.  204 
 205 
Formatted: Superscript
The research capacity of African clinicians, researchers and health administrators should be 206 
built up for them to conduct basic epidemiological research such as incidence, prevalence, 207 
mortality and CFR among HIV-exposed children in various health facilities and communities. 208 
Researchers should be encouraged to disseminate their findings to their immediate 209 
communities and Departments of Health and to publish their findings in peer-reviewed 210 
journals. Established research groups such as Global Burden of Diseases Network should 211 
include the burden of vaccine-preventable diseases in HIV-exposed and non-exposed children 212 
as part of their regular or annual publications. Other African countries should emulate South 213 
Africa in increasing their research activities and outputs with respect to HIV-exposed children. 214 
 215 
There is a need to advocate for an equitable share of healthcare budgeting and finance at every 216 
level of governance in African countries. This will help in ensuring that there is a fair share of 217 
resources for preventive and treatment services such as vaccination and antiretroviral therapy 218 
for HIV-exposed children. African countries should, as a matter of urgency, complete the 219 
introduction of newer and important vaccines such as rotavirus vaccine, Hib vaccine and 220 
pneumococcal vaccine. These should be included as part of their current national immunisation 221 
programme schedule.95 According to WHO, the global coverage for both pneumococcal 222 
vaccine and rotavirus vaccines were as little as 44 percent and 25 percent respectively.100 223 
African countries should be supported in developing vaccine procurement budgets, 224 
procurement practices, and capacity development for vaccine planning and advocacy.1062 225 
 226 
Study limitations 227 
This study was limited by several factors beyond the reviewers’ control. We planned to review 228 
all the vaccine-preventable diseases associated with vaccines included in the national 229 
immunisation programme schedule in sub-Saharan Africa, however, we could not find articles 230 
that met the eligibility criteria for some of the diseases. Secondly, there was high heterogeneity 231 
even with sub-group analysis between included studies, which implies the possibility of other 232 
contributory factors associated with the diseases. Some of the studies did not include relevant 233 
information such as antiretroviral coverage, CD4 count, viral load, vaccination status and other 234 
contributory factors. Thirdly, we could not include many studies because the diagnostic criteria 235 
for different vaccine-preventable diseases were not specified and clearly defined.  236 
 237 
Furthermore, the presence of various limitations did not stop us from making some meaningful 238 
conclusions from this study. This review gives a clearer picture of the burden and trend of TB 239 
and able to have insights about the burden of other diseases as well despite having a small 240 
number of studies included in this review. African investigators should as a matter of priority 241 
have proper diagnostic criteria and documentation for diseases for all HIV-infected and HIV-242 
exposed children treated at the health facilities across the region. Key parameters such as CD4 243 
counts, vaccination status etc. should be included in future studies. 244 
 245 
 246 
Conclusions 247 
This systematic review and meta-analysis provide an all-inclusive analysis of the incidence 248 
rates, prevalence and CFR of various vaccine-preventable diseases. This study shows that some 249 
vaccine-preventable diseases still have high incidence, prevalence and CFRs in HIV-infected 250 
and HIV-exposed children. There was also the dearth of research activities on vaccine-251 
preventable disease studies concerningwith respect to HIV-infected and HIV-exposed 252 
uninfected children in many African countries. The findings are useful in advocating for a more 253 
equitable share of healthcare financing especially for preventive services such as vaccination 254 
of both HIV-exposed and non-exposed children in order toto reduce the burden of vaccine-255 
preventable diseases.  256 
 257 
 258 
Methods and design 259 
This systematic review was developed in line with the Preferred Reporting Items for Systematic 260 
Review and Meta-Analysis (PRISMA) 2015 statement.1073 The review was registered with 261 
PROSPERO (International prospective register of systematic reviews) (CRD42018095341). 262 
Inclusion criteria 263 
Type of participants: The review included sub-Saharan African children who are HIV-infected 264 
or HIV-exposed and aged <18 years old. 265 
Types of outcome:  266 
We included studies that reported the incidence, prevalence and case-fatality rates (CFR) as 267 
outcomes in HIV-infected and HIV-exposed children. 268 
Primary outcomes 269 
Prevalence was defined as proportions of all individuals suspected of having specific vaccine-270 
preventable diseases with confirmed laboratory diagnosis or proportions of individuals 271 
fulfilling clinical case definition for specific vaccine-preventable diseases. Incidence was 272 
defined as the number of new cases of different vaccine-preventable diseases that occur during 273 
a given period in the defined population. 274 
We also determined the trend in the incidence and/or prevalence of vaccine-preventable 275 
diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 276 
2018. 277 
Secondary outcomes 278 
We included CFRs associated with vaccine-preventable diseases. Case fatality was described 279 
as mortality among confirmed or probable cases for a specific vaccine-preventable disease. 280 
Type of studies: The review included cohort studies, case-control studies, cross-sectional 281 
studies and other observational studies. We planned to include studies that involved any of 282 
the following vaccine-preventable diseases: 283 
i. Tuberculosis  284 
ii. Poliomyelitis 285 
iii. Hepatitis B virus infection  286 
iv. Rotavirus gastroenteritis 287 
v. Diphtheria 288 
vi. Tetanus 289 
vii. Pertussis 290 
viii. Pneumococcal diseases 291 
ix. Measles  292 
x. Rubella 293 
xi. Yellow fever 294 
 295 
Exclusion criteria 296 
 Intervention studies 297 
 Unclear diagnostic criteria 298 
 299 
Search strategy methods for the identification of studies 300 
A comprehensive search strategy was developed to identify relevant studies up to August 2018, 301 
regardless of publication status or language. Scopus, Web of Science, MEDLINE via PubMed 302 
and CINAHL were searched for relevant publications. The search process was complemented 303 
by reviewing citations of all identified eligible studies. We also searched relevant World Health 304 
Organization position papers and documents on vaccines. (See Appendix for PubMed search 305 
strategy).  306 
Selection of eligible studies 307 
Two of the authors, (OOA and AA) screened the search results using the abstract titles. They 308 
also independently went through the full text of potential studies to assess whether they met 309 
the required inclusion criteria. Non-human studies, reviews, intervention studies, letters, 310 
commentaries and editorials were excluded. Studies not written in English, French, German, 311 
Spanish, Portuguese or Dutch were excluded. We resolved disagreements by consensus.  312 
Data collection process 313 
The two authors then extracted data from text, tables and figures. The data were recorded on a 314 
standardised form. We planned to contact authors of included studies in case of unclear or 315 
missing data.                                  316 
The following data were extracted from selected studies: 317 
 Study characteristics including period and design. 318 
 Vaccine-preventable diseases patient characteristics such as age and HIV status.  319 
 Prevalence or incidence of vaccine-preventable diseases: confirmed cases and cases 320 
meeting the clinical definition. 321 
 Diagnostic methods: laboratory methods and clinical case definitions. 322 
 Death attributed to vaccine-preventable diseases. 323 
Risk of bias in individual studies 324 
The risk of bias and quality of the included studies were assessed with the Newcastle-Ottawa 325 
Quality Scale.1084 The criteria assessed included the following (1) selection of participants, 326 
(2) comparability, (3) exposure, and (4) outcome.  327 
 328 
Data synthesis 329 
OOA summarised the incidence and prevalence of various vaccine-preventable diseases. 330 
Where possible, incidence and prevalence data from each of the included studies were 331 
combined by random effects meta-analysis in accordance with the Mantel-Haenszel method. 332 
Heterogeneity was evaluated using the Chi-squared test of homogeneity (significant for P < 333 
0.1) and quantified using the I-squared statistic (>50% substantial heterogeneity).1095 Subgroup 334 
analyses were conducted in cases with substantial heterogeneity. Subgroup analysis was 335 
conducted using the following variables: period of study (1991- 2000, 2001-2010 and 2011 – 336 
2018). We also used funnel plot regression to assess publication bias. STATA software version 337 
14.0 (STATA Corporation, College Station, TX, USA) was used to do all calculations, the 338 
meta-analysis and generate forest plots.11006 339 
Additional analyses: Trend analysis 340 
We examined time trends in the incidence and prevalence of vaccine-preventable diseases 341 
estimates using Poisson regression models with the prevalence estimates as the outcome 342 
variable and the calendar year of the publication as the predictor. This method allows for 343 
estimation of time trends across individual calendar years to obtain average annual percentage 344 
change (AAPC), assuming thatif the rate of change is at a constant rate of the previous year. 345 
11107 The Poisson regression procedure fits a model of the following form: 346 
                             
  0 1log log( )yprevalence b b y sample size                                (1) 347 
where ‘cases’ equal prevalence estimates reported per year, log is the natural log, b0 is the 348 
intercept, b1 is the trend, y is the year – given as 0, 1, 2, … 18 (year 0 is 1970, year 1 is 1971, 349 
and so on to 2014), and log of ‘sample size’ was entered as the offset. The AAPC was calculated 350 
using the following formula: 351 
                                             
 1 1 100bAAPC e  
                                                (2) 352 
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Search 
Add to 
builder 
Query 
Items 
found 
#6  Add Search ((((#1) AND #2) AND #3) AND #4) AND #5 Sort by: Best Match 1364  
#4  Add Search (newborn* OR bab* OR infan* OR child* OR adolescen* OR teen*) Sort 
by: Best Match 
3843580  
#2  Add Search (tuberculosis OR TB OR poliomyelitis OR polio OR rotavirus OR diphtheria 
OR tetanus OR pertussis OR pneumococcal OR pneumonia OR measles OR 
"yellow fever" OR "Hepatitis B" OR "Haemophilus influenza" OR "Hemophilus 
influenza" OR influenza) Sort by: Best Match 
707401  
#5  Add Search (incidence OR prevalence OR mortality) Sort by: Best Match 3171459  
#3  Add Search ("HIV infected" OR "HIV exposed" OR "HIV-infected" OR "HIV-exposed" OR 
"HIV positive" OR "HIV exposed uninfected") Sort by: Best Match 
74539  
#1  Add Search (Angola OR Benin OR Botswana OR "Burkina Faso" OR Burundi OR 
Cameroon OR "Cape Verde" OR "Central African Republic" OR Chad OR Congo OR 
"Democratic Republic of Congo" OR DRC OR Djibouti OR "Equatorial Guinea" OR 
Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR "Guinea Bissau" OR 
Guinea OR "Ivory Coast" OR "Cote d’Ivoire" OR Kenya OR Lesotho OR Liberia OR 
Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mozambique OR 
Namibia OR Niger OR Nigeria OR "Republic of the Congo" OR Reunion OR Rwanda 
OR Senegal OR Seychelles OR "Sierra Leone" OR "Sao Tome and Principe" OR 
Somalia OR "South Africa" OR "South Sudan" OR Sudan OR Swaziland OR 
Tanzania OR Togo OR Tunisia OR Uganda OR Zambia OR Zimbabwe OR Africa OR 
"sub Saharan Africa") Sort by: Best Match 
558013  
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Table 1: Characteristics of the study population 
First author and year Study period Study design Country Sample size  VPD Outcomes HIV 
status 
Quality 
scores 
Abuogi 201315 2009 - 2010 Cohort Kenya 689 Tuberculosis C, I, P HI 7 
Adams 201416 2006 - 2012 Cross-sectional Tanzania 1193 Tuberculosis C, P HI 4 
Alemu 201617 2009 - 2014 Cohort Ethiopia 645 Tuberculosis I HI 6 
Anigilaje 201618 2010 - 2013 Cohort  Nigeria 368 Tuberculosis P HI 8 
Auld 201419 2004 - 2008 Cohort  Cote d' Ivoire 2110 Tuberculosis I, P HI 8 
Bakeera 201120 2003 - 2006 Cohort  Uganda 1806 Tuberculosis I, C HI 8 
Bonnet 201821 2012 - 2014 Cohort Uganda 113 Tuberculosis C HI 7 
Braitstein 200922 2001 - 2007 Cohort Kenya 6,535 Tuberculosis I, P HI 8 
Buck 201323 2010 Cohort Malawi 4874 Tuberculosis C, P HI 8 
Carlucci 201724 2012 - 2014 Cohort  Multiple  386 Tuberculosis C HI 8 
Cavanaugh 201225 2006 - 2007 Cross-sectional Kenya 323 Tuberculosis C HI 6 
Chaya 201626 2006 - 2011 Cross-sectional South Africa 47 Tuberculosis I  HI 6 
Cruz 201527 NR Cohort Botswana 100 Tuberculosis P HI 6 
Dangor 201328 2005 - 2009 Time-series analysis South Africa 1985 Tuberculosis I HI 7 
De Maayar 201129 NR Cross-sectional South Africa 58 Tuberculosis P HI 7 
Ebonyi 201630 2005 - 2013 Cohort  Nigeria 260 Tuberculosis C HI 8 
Ebonyi 2016b31 2005-2012 Cohort  Nigeria 876 Tuberculosis P HI 8 
Elenga 200532 2000-2003 Cohort Cote d' Ivoire 282 Tuberculosis I HI 8 
Ferrand 201033 2007-2008 Cross-sectional Zimbabwe 139 Tuberculosis P HI 7 
Hall 201734 2005-2008 Cohort South Africa 224 Tuberculosis C HI 8 
Hesseling 2009a35 2004-2006 Cross-sectional  South Africa 3321 Tuberculosis C HI 6 
Hesseling 200536 1992-2000 Cohort South Africa 93 Tuberculosis C HI 8 
Hesseling 200637 2002-2005 Cohort South Africa 108 Tuberculosis C, P HI 7 
Hesseling 2009b38 2004-2006 Cross-sectional South Africa 3321 Tuberculosis I, P HI 7 
Hicks 201439 2009-2010 Cohort  South Africa 64 Tuberculosis C HI 6 
Jeena 200040 1995-1998 Cross-sectional  South Africa 27 Tuberculosis P HI 5 
Kasambira 201141 2006-2009 Cross-sectional  South Africa 270 Tuberculosis P HI 6 
Madhi 2000b42 1996-1997 Cross-sectional South Africa 67 Tuberculosis C HI 5 
Meyers 200043 1996 Cross-sectional South Africa 144 Tuberculosis P HI 5 
Table 1
Mwangwa 201744 2012-2013 Cohort Multiple  17 Tuberculosis C HI 7 
Obiagwu 201345 2010 Cross-sectional Nigeria 22 
Tuberculosis, 
Measles P HI 
6 
Okechukwu 201146 2007-2008 Cross-sectional Nigeria 210 Tuberculosis C, P HI 6 
Osman 201747 2005-2012 Cohort South Africa 3143 Tuberculosis C HI 6 
Padayatchi 200648 1993-2002 Cross-sectional South Africa 6 Tuberculosis C HI 5 
Palme 200249 1995-1997 Cohort Ethiopia 58 Tuberculosis C HI 6 
Patel 201350 2007-2009 Cohort Congo DRC 31 Tuberculosis C HI 7 
Robinson 200751 1999-2001 Case-control South Africa 47 Tuberculosis P HI 6 
Rose 201252 2008-2010 Cohort Tanzania 54 Tuberculosis P HI 6 
Schaaf 200753 2003-2005 Cross-sectional South Africa 133 Tuberculosis C HI 5 
Soeters 200554 2000-2001 Cross-sectional South Africa 43 Tuberculosis C HI 4 
Walters 201455 2003-2010 Cohort South Africa 494 Tuberculosis C HI 6 
Walters 200856 2003-2005 Cross-sectional South Africa 137 Tuberculosis C HI 6 
Westerlund 201457 2003-2008 Cohort Ethiopia 138 Tuberculosis P HI 7 
Wiseman 201158 2004-2006 Cross-sectional South Africa 52 Tuberculosis C HI 5 
Yotebieng 201059 2004-2008 Cohort South Africa 573 Tuberculosis C HI 6 
Kouakoussui 200460 2003 Cohort Cote d’Ivoire 270 Tuberculosis I HI 7 
Abera 201461 2014 Cross-sectional Ethiopia 253 HBV infection P HI 6 
Ashir 200962 2007 Case-control Nigeria 284 HBV infection P HI 5 
Beghin 201763 2014 Cross-sectional South Africa 183 HBV infection P HI 6 
Chotun 201564 2011 - 2012 Cross-sectional  South Africa 1000 HBV infection P HE 6 
Uleanya 201665 NR Cross-sectional Nigeria 140 HBV infection P HI 4 
Dziuban 201366 2009 - 2011 Cross-sectional Swaziland 500 HBV infection P HI 3 
Ikpeme 201367 2010-2011 Cross-sectional Nigeria 166 HBV infection P HI 4 
Jooste 201668 2015-2016 Cohort South Africa 625 HBV infection P HI 7 
Muro 201369 2006-2008 Cross-sectional Tanzania 157 HBV infection P HI 5 
Mutwa 201370 2010 Cohort Rwanda 88 HBV infection P HI 7 
Nwolisa 201371 2010 Cross-sectional Nigeria 139 HBV infection P HI 4 
Sadoh 201172 NR Cross-sectional Nigeria 155 HBV infection P HI 5 
Telatela 200773 2006 Cross-sectional Tanzania 167 HBV infection P HI 4 
Varo 201674 2008-2010 Cross-sectional Malawi 91 HBV infection P HI 3 
Moss 200275 1998-2000 Cross-sectional Zambia 93 Measles P HI 6 
Wirth 201576 2009-2010 Case-control Botswana 189 Measles C HI 5 
du Plessis 201814 2013 - 2015 Cross-sectional South Africa 300 Pertussis  P HI 6 
Gill 201677 2015 Cohort Zambia 347 Pertussis I HI 7 
Soofie 201678 2015 Cross-sectional South Africa 599 Pertussis C, I, P HE 5 
Johnson 200079 1996-1997 Cross-sectional South Africa 31 
Rotavirus 
gastroenteritis P HI 
6 
Moyo 201480 2010-2011 Case-control Tanzania 26 
Rotavirus 
gastroenteritis P HI 
5 
Asbjörnsdóttir 201381 
1999-2002 Cohort Kenya 
388 
Pneumococcal 
infection C,I HI 
6 
Nathoo 199682 1993-1994 Cohort Zimbabwe 168 
Pneumococcal 
infection P HI 
7 
Zar 200183 1998 Cross-sectional South Africa 151 
Pneumococcal 
infection P HI 
6 
Jones 199884 1996 Cross-sectional South Africa 25 
Pneumococcal 
infection C HI 
5 
Roca 201085 2004-2006 Cross-sectional Mozambique 54 
Pneumococcal 
infection C HI 
6 
Cohen 201686 2009 - 2013 Cross-sectional South Africa 211 
Pneumococcal 
infection I HEU,HI 
4 
Nunes 201187 2003-2008 Cross-sectional South Africa 938 
Pneumococcal 
infection I HI 
6 
von Mollendorf 2017a88 2009–2013 Cross-sectional South Africa 495 
Pneumococcal 
infection C, I HI 
5 
von Gottberg 201389 2003-2008 Cross-sectional  South Africa 1749 
Pneumococcal 
infection I HI 
5 
Nyasulu 201190 2003-2005 Cross-sectional South Africa 1124 
Pneumococcal 
infection C HI 
6 
  
NR- Not recorded; C- Case-fatality rate; I – Incidence; P – Prevalence; Hib- Haemophilus influenzae type b; HI- HIV-infected; HE- HIV-exposed; HEU – HIV-exposed uninfected; VPD - vaccine–preventable diseases. 
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Search 
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Items 
found 
#6  Add  Search ((((#1) AND #2) AND #3) AND #4) AND #5 Sort by: Best Match 1364  
#4  Add  Search (newborn* OR bab* OR infan* OR child* OR adolescen* OR teen*) Sort 
by: Best Match 
3843580  
#2  Add  Search (tuberculosis OR TB OR poliomyelitis OR polio OR rotavirus OR diphtheria 
OR tetanus OR pertussis OR pneumococcal OR pneumonia OR measles OR 
"yellow fever" OR "Hepatitis B" OR "Haemophilus influenza" OR "Hemophilus 
influenza" OR influenza) Sort by: Best Match 
707401  
#5  Add  Search (incidence OR prevalence OR mortality) Sort by: Best Match 3171459  
#3  Add  Search ("HIV infected" OR "HIV exposed" OR "HIV-infected" OR "HIV-exposed" OR 
"HIV positive" OR "HIV exposed uninfected") Sort by: Best Match 
74539  
#1  Add  Search (Angola OR Benin OR Botswana OR "Burkina Faso" OR Burundi OR 
Cameroon OR "Cape Verde" OR "Central African Republic" OR Chad OR Congo OR 
"Democratic Republic of Congo" OR DRC OR Djibouti OR "Equatorial Guinea" OR 
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